OBJECTIVE: To determine the characteristics of oligoclonal bands that are frequently detected by serum protein electrophoresis (SPEP) and immunofixation electrophoresis (IFE) after stem cell transplantation. METHODS: We retrospectively analyzed 56 patients with multiple myeloma (MM) undergoing transplantation, and standard immunofixation electrophoresis was used to identify and quantify paraproteins. RESULTS: The median follow-up was 35 months (range, 10-76 months) and 21 patients relapsed. Twelve (25.0%) demonstrated oligoclonal bands after a median time 1.4 months (range, 1-3 months), with a median duration of 5.8 months (range, 1-15 months). The majority patients with oligoclonal bands had normal quantities of immunoglobulins and the one year event free survival (EFS) was 92%, even higher than for patients without OBs (P=0.002). CONCLUSION: Oligoclonal bands frequent develop post-transplantation in MM cases. In the vast majority of patients, they may not represent relapsed disease, and more likely represent a transient phenomenon representing recovery of impaired immunoglobulin production.
OBJECTIVE: To determine the characteristics of oligoclonal bands that are frequently detected by serum protein electrophoresis (SPEP) and immunofixation electrophoresis (IFE) after stem cell transplantation. METHODS: We retrospectively analyzed 56 patients with multiple myeloma (MM) undergoing transplantation, and standard immunofixation electrophoresis was used to identify and quantify paraproteins. RESULTS: The median follow-up was 35 months (range, 10-76 months) and 21 patients relapsed. Twelve (25.0%) demonstrated oligoclonal bands after a median time 1.4 months (range, 1-3 months), with a median duration of 5.8 months (range, 1-15 months). The majority patients with oligoclonal bands had normal quantities of immunoglobulins and the one year event free survival (EFS) was 92%, even higher than for patients without OBs (P=0.002). CONCLUSION: Oligoclonal bands frequent develop post-transplantation in MM cases. In the vast majority of patients, they may not represent relapsed disease, and more likely represent a transient phenomenon representing recovery of impaired immunoglobulin production.
Authors: Marian F Schmitz; Henny G Otten; Laurens E Franssen; Suzanne van Dorp; Theo Strooisma; Henk M Lokhorst; Niels W C J van de Donk Journal: Haematologica Date: 2014-09-05 Impact factor: 9.941
Authors: H Caillon; T Dejoie; A-G Le Loupp; C Azoulay-Fauconnier; D Masson; P Moreau; M Denis; H Avet-Loiseau Journal: Blood Cancer J Date: 2013-10-25 Impact factor: 11.037
Authors: Luiza Soares Vieira da Silva; Edvan de Queiroz Crusoe; Lais Rocha Guimarães de Souza; Carlos Sérgio Chiattone; Vânia Tietsche de Moraes Hungria Journal: Rev Bras Hematol Hemoter Date: 2017-07-01